Literature DB >> 34284791

Response to Lawrence DJ: the global summit on the efficacy and effectiveness of spinal manipulative therapy for the prevention and treatment of non-musculoskeletal disorders: a systematic review of the literature.

Pierre Côté1,2,3,4, Jan Hartvigsen5,6, Iben Axén7,8, Charlotte Leboeuf-Yde9, Melissa Corso10,11, Heather Shearer11,12, Jessica Wong10,11,13, Andrée-Anne Marchand14, J David Cassidy13, Simon French15, Gregory N Kawchuk16, Silvano Mior11,17, Erik Poulsen5, John Srbely18, Carlo Ammendolia12,19, Marc-André Blanchette14, Jason W Busse20, André Bussières14,21, Carolina Cancelliere10,11, Henrik Wulff Christensen6, Diana De Carvalho22, Katie De Luca15, Alister Du Rose23, Andreas Eklund7, Roger Engel15, Guillaume Goncalves24, Jeffrey Hebert25, Cesar A Hincapié26, Maria Hondras27, Amanda Kimpton28, Henrik Hein Lauridsen5, Stanley Innes29, Anne-Laure Meyer24, David Newell30, Søren O'Neill9,31, Isabelle Pagé14, Steven Passmore32, Stephen M Perle33, Jeffrey Quon34, Mana Rezai11, Maja Stupar17, Michael Swain15, Andrew Vitiello35, Kenneth Weber36, Kenneth J Young37, Hainan Yu10,11.   

Abstract

Entities:  

Year:  2021        PMID: 34284791      PMCID: PMC8290565          DOI: 10.1186/s12998-021-00380-7

Source DB:  PubMed          Journal:  Chiropr Man Therap        ISSN: 2045-709X


× No keyword cloud information.
Thank you for the opportunity to respond to the Letter to the Editor by Dana J. Lawrence. In his letter, Lawrence states that the results of our systematic review may be due to bias. However, he does not adequately substantiate his claims. First, Lawrence perceived that we “brushed away” the possibility of reviewer bias. This comment is surprising because, as described in the paper, we carefully planned for possible reviewer bias and took several methodological steps to minimize its potential impact. Specifically, we: 1) developed an instruction manual for critical appraisal that we distributed to all reviewers prior to the Global Summit; 2) used the Scottish Intercollegiate Guidelines Network (SIGN) criteria, a standardized critical appraisal tool, to assess the risk of bias of randomized controlled trials; 3) adapted the language of the SIGN tool to minimize the risk of misinterpretation of the critical appraisal items; 4) provided detailed notes that accompanied the SIGN checklist, and edited to match the purpose of this review; 5) conducted three rounds of independent reviews to ensure that the risk of bias assessment was consistent across reviewers; 6) undertook a quality control assessment by two independent reviewers, who reviewed all critical appraisal checklists and risk of bias ratings; and 7) invited all Global Summit participants to independently review and vote on the final risk of bias assessment results; the risk of bias table was approved by 98.0% (49/50) of participants. Therefore, the position advanced by Lawrence that we “brushed away” the possibility of reviewer bias is not justified. Second, Lawrence states that publication bias may be responsible for our findings. He wrote: “… publication bias tilted toward positive, not negative, findings have been demonstrated even in Cochrane reviews themselves.” and he uses the study by Kicinski et al. to support his assertion [1]. This indicates that Lawrence misinterpreted the concept of publication bias in this instance. In their study of systematic reviews included in the Cochrane database, Kicinski et al. reported that: “In the meta-analyses of efficacy, outcomes favoring treatment had on average a 27% (95% Credible Interval (CI): 18% to 36%) higher probability to be included than other outcomes.” [1] We refer Lawrence to our discussion where we clearly stated: “Finally, publication bias may be present in this field of research. However, it is unlikely that publication bias compromised the validity of our results because studies most unlikely to be published are those that failed to obtain a ‘positive’ result.” In other words, we are in agreement with Kicinski et al. and disagree with Lawrence’s conclusion. In fact, our position is consistent with a large body of methodological literature which clearly indicates that a trial is more likely to be published if the results favor a specific intervention (positive results) compared to a trial which does not support an effect of an intervention (negative results) [1-13]. We would like to remind Lawrence that we identified and critically appraised studies regardless if they had “negative” or “positive” results. However, the methodological quality of “positive” trials was low and their results could not be used to inform our synthesis. Third, Lawrence indicated that clinicians did not have a voice in the project. We respectfully disagree with this assertion. Several participants to the Global Summit maintain an active practice and most participants have had long and successful clinical careers. In summary, the statements made by Lawrence about our methodology are incorrect and ill informed. While we thank Lawrence for his interest in our work, his statements about our methodology are in our opinion misconstrued and hence not appropriate.
  13 in total

1.  Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors.

Authors:  An-Wen Chan; Douglas G Altman
Journal:  BMJ       Date:  2005-01-28

2.  Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards.

Authors:  K Dickersin; Y I Min; C L Meinert
Journal:  JAMA       Date:  1992-01-15       Impact factor: 56.272

3.  Fate of biomedical research protocols and publication bias in France: retrospective cohort study.

Authors:  Evelyne Decullier; Véronique Lhéritier; François Chapuis
Journal:  BMJ       Date:  2005-06-20

4.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

5.  Publication bias in meta-analyses from the Cochrane Database of Systematic Reviews.

Authors:  Michal Kicinski; David A Springate; Evangelos Kontopantelis
Journal:  Stat Med       Date:  2015-05-18       Impact factor: 2.373

6.  Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals.

Authors:  Carolina Riveros; Agnes Dechartres; Elodie Perrodeau; Romana Haneef; Isabelle Boutron; Philippe Ravaud
Journal:  PLoS Med       Date:  2013-12-03       Impact factor: 11.069

Review 7.  Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials.

Authors:  Kerry Dwan; Douglas G Altman; Mike Clarke; Carrol Gamble; Julian P T Higgins; Jonathan A C Sterne; Paula R Williamson; Jamie J Kirkham
Journal:  PLoS Med       Date:  2014-06-24       Impact factor: 11.069

8.  Publication of clinical trials supporting successful new drug applications: a literature analysis.

Authors:  Kirby Lee; Peter Bacchetti; Ida Sim
Journal:  PLoS Med       Date:  2008-09-23       Impact factor: 11.069

9.  Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.

Authors:  Kristin Rising; Peter Bacchetti; Lisa Bero
Journal:  PLoS Med       Date:  2008-11-25       Impact factor: 11.069

Review 10.  Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review.

Authors:  Kerry Dwan; Carrol Gamble; Paula R Williamson; Jamie J Kirkham
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.